New hope for rare Virus-Linked cancers: immunotherapy drug shows promise
NCT ID NCT03258567
First seen Nov 20, 2025 · Last updated Jun 11, 2026 · Updated 32 times
Summary
This study tests whether the drug nivolumab can slow or stop the growth of certain cancers linked to the Epstein-Barr virus. About 40 people aged 12 and older with these cancers who have no standard treatment options will receive nivolumab every two weeks. The goal is to see if the drug shrinks tumors and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.